Mediterranean Journal of Hematology and Infectious Diseases Outcome of Allogeneic Stem Cell Transplantation Conditioninig Regimen in Patients with Idiopathic Myelofibrosis: the G.i.t.m.o. Experience Intermediate or High Dupriez Score. Conditioning Regimens Were Based on Fludarabine plus Busulphan in
暂无分享,去创建一个
R. Fanin | A. Bosi | M. Isola | A. Bacigalupo | G. Visani | P. Di Bartolomeo | F. Patriarca | P. Pioltelli | M. V. van Lint | A. Sperotto | P. Iacopino | A. Iori | M. Musso | B. Bruno
[1] G. Barosi,et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type , 2010, Bone Marrow Transplantation.
[2] H. Einsele,et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2009, Blood.
[3] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[4] R. Fanin,et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) , 2008, Haematologica.
[5] C. Pascutto,et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). , 2008, Blood.
[6] D. Dingli,et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. , 2007, Leukemia research.
[7] R. Fanin,et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome , 2007, Leukemia.
[8] F. M. Stewart,et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] N. Kröger,et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. , 2007, Blood.
[10] A. Zander,et al. Rapid Regression of Bone Marrow Fibrosis after Dose-Reduced Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. , 2006 .
[11] L. Nilsson,et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens , 2006, British journal of haematology.
[12] S. Forman,et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] R. Mesa,et al. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic , 2006, Cancer.
[14] G. Barosi,et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2006, Current opinion in hematology.
[15] R. Hoffman,et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. , 2005, Blood.
[16] J. Panse,et al. Pilot study of reduced‐intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis , 2005, British journal of haematology.
[17] A. Elmaagacli,et al. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis , 2004, Bone Marrow Transplantation.
[18] H. Deeg,et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. , 2003, Blood.
[19] W Hasegawa,et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers , 2003, Bone Marrow Transplantation.
[20] A. Verma,et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. , 2002, Blood.
[21] H. Deeg,et al. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. , 2001, Blood.
[22] H. Deeg,et al. Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation , 2001, Leukemia.
[23] F. Frassoni,et al. Reduced intensity thiotepa–cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age , 2000, British journal of haematology.
[24] A. Tefferi. Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.
[25] A. Nagler,et al. The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia. , 1999, Leukemia research.
[26] H. Deeg,et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. , 1999, Blood.
[27] P. Morel,et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.
[28] F. Benvenuto,et al. Thiotepa Cyclophosphamide Followed by Granulocyte Colony-Stimulating Factor Mobilized Allogeneic Peripheral Blood Cells in Adults With Advanced Leukemia , 1996 .
[29] F. Benvenuto,et al. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. , 1996, Blood.
[30] F. Aversa,et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.
[31] B. Teicher,et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. , 1988, Journal of the National Cancer Institute.